PAK1 (Ab-199) Antibody

What is PAK1 and what cellular functions does it regulate?

PAK1 (p21-activated kinase 1) is a serine/threonine protein kinase that plays crucial roles in multiple cellular processes. It functions downstream of integrins and receptor-type kinases and is involved in:

• Cytoskeleton dynamics and reorganization of actin stress fibers

• Cell adhesion, migration, and proliferation

• Apoptosis regulation (can directly phosphorylate BAD to protect cells against apoptosis)

• Mitosis progression

• Vesicle-mediated transport processes

• JNK MAP kinase pathway regulation as a GTPase effector

PAK1 serves as a key mediator linking Rho-related GTPases CDC42 and RAC1 to downstream signaling pathways. It phosphorylates and activates MAP2K1, thereby mediating activation of downstream MAP kinases, which contributes to its diverse cellular functions .

What is the PAK1 (Ab-199) antibody and what epitope does it recognize?

PAK1 (Ab-199) antibody is a rabbit polyclonal antibody specifically designed to recognize the region surrounding the serine 199 phosphorylation site of human PAK1. The antibody is generated using a synthesized non-phosphopeptide derived from human PAK1/2 with the amino acid sequence around the phosphorylation site of serine 199 (T-K-S-V-Y) . This antibody detects endogenous levels of total PAK1/2 protein and is not phospho-specific, meaning it recognizes both phosphorylated and non-phosphorylated forms of PAK1 at this site .

What are the validated applications for PAK1 (Ab-199) antibody?

The PAK1 (Ab-199) antibody has been validated for multiple research applications, including:

• Western Blotting (WB): Recommended dilution range of 1:500-1:3000

• Immunohistochemistry (IHC): Recommended dilution range of 1:50-1:100

• ELISA: Recommended dilution of 1:1000

• Immunofluorescence/Immunocytochemistry (IF/ICC): Recommended dilution range of 1:100-1:500

These applications have been validated using human, mouse, and rat samples, making this antibody suitable for cross-species research .

How should I optimize Western blot conditions for PAK1 (Ab-199) antibody?

For optimal Western blot results with PAK1 (Ab-199) antibody:

• Sample preparation: Extract proteins using a lysis buffer containing phosphatase inhibitors to preserve PAK1 phosphorylation states if studying phosphorylation dynamics.

• Protein loading: Load 20-40 μg of total protein per lane for cell lysates.

• Gel percentage: Use 8-10% polyacrylamide gels for optimal separation around PAK1's molecular weight (68 kDa).

• Transfer conditions: Transfer to PVDF or nitrocellulose membranes at 100V for 60-90 minutes.

• Blocking: Block with 5% non-fat milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody incubation: Dilute PAK1 (Ab-199) antibody 1:500-1:3000 in blocking buffer and incubate overnight at 4°C.

• Detection system: Use appropriate HRP-conjugated secondary antibodies and ECL detection system.

The antibody detects a band at approximately 68 kDa corresponding to PAK1 protein .

What controls should I include when using PAK1 (Ab-199) antibody in my experiments?

To ensure experimental validity and reliable interpretation of results:

• Positive control: Include lysates from cell lines known to express PAK1, such as K562, 293, or 3T3 cells, which have been validated with this antibody .

• Negative control: Consider using:

  • PAK1 knockdown/knockout samples if available

  • Primary antibody omission control

  • Isotype control using non-specific rabbit IgG at the same concentration

• Loading control: Include detection of housekeeping proteins such as GAPDH, β-actin, or α-tubulin to ensure equal loading across samples.

• Peptide competition assay: Pre-incubate the antibody with excess immunogenic peptide to confirm specificity, as demonstrated in validation data for phospho-specific PAK1 antibodies .

• Cross-reactivity assessment: If studying specific PAK isoforms, consider validating against recombinant PAK1 and PAK2 proteins to confirm specificity .

How can I use PAK1 (Ab-199) antibody for immunohistochemistry of tissue samples?

For effective immunohistochemical staining:

• Tissue preparation:

  • Use formalin-fixed, paraffin-embedded (FFPE) tissue sections (4-6 μm thick)

  • Perform heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

• Blocking:

  • Block endogenous peroxidase activity with 0.3-3% hydrogen peroxide

  • Block non-specific binding with 5-10% normal serum from the same species as the secondary antibody

• Antibody incubation:

  • Dilute PAK1 (Ab-199) antibody 1:50-1:100 in blocking buffer

  • Incubate overnight at 4°C or 2 hours at room temperature

• Detection:

  • Use biotin-streptavidin HRP conjugate or polymer detection system

  • Develop with DAB or other appropriate chromogen

  • Counterstain with hematoxylin, dehydrate, and mount

• Controls:

  • Include positive control tissues (human placenta or brain tissue have been validated)

  • Include negative controls (primary antibody omission)

  • Consider peptide competition controls for specificity verification

The antibody has been successfully used for IHC analysis in human brain and placenta tissues .

How does the phosphorylation state of PAK1 at Ser199 relate to its function?

PAK1 phosphorylation at Ser199 represents an important regulatory mechanism:

• Activation dynamics: Ser199 phosphorylation is one of several phosphorylation events that occur during PAK1 activation, though it is distinct from the critical activation loop phosphorylation at Thr423. While Thr423 phosphorylation is directly linked to kinase activation, Ser199 phosphorylation may serve as a regulatory modification that influences protein-protein interactions or subcellular localization .

• Cellular context: Phosphorylation at Ser199/204 has been observed during wound healing in epithelial cells, suggesting a role in contact inhibition and cell migration processes. Using phospho-specific antibodies against these sites, researchers have tracked the spatiotemporal activation of PAK1 during wound closure .

• Signaling integration: This phosphorylation appears to be regulated by upstream kinases in response to various cellular stimuli. Unlike the GTPase-dependent activation mechanisms, Ser199 phosphorylation may represent alternative activation pathways or fine-tuning mechanisms for PAK1 activity .

• Functional outcomes: Research suggests that different phosphorylation combinations on PAK1 may lead to distinct functional outcomes or substrate preferences, allowing for context-specific signaling .

To study specific functions of PAK1 Ser199 phosphorylation, researchers often use phospho-specific antibodies like anti-PAK1 (phospho S199) in combination with phosphorylation site mutants (S199A to prevent phosphorylation or S199D/E to mimic constitutive phosphorylation) .

What is the role of PAK1 in cancer, particularly in glioblastoma multiforme (GBM)?

PAK1 demonstrates significant oncogenic potential in GBM:

• Expression correlation: PAK1 is significantly upregulated in GBM compared to low-grade gliomas. Higher PAK1 expression correlates with shorter survival in both CGGA and TCGA datasets, indicating its potential as a prognostic marker .

• Molecular mechanisms:

  • PAK1 promotes GBM growth through enhancing autophagy under hypoxic conditions

  • PAK1 directly phosphorylates ATG5 at the conserved T101 residue

  • Hypoxia induces acetylation of PAK1 at K420, enhancing its interaction with ATG5

  • These modifications promote ATG12-ATG5-ATG16L1 complex formation, facilitating autophagosome formation

• Functional impact: Knockdown of PAK1 significantly suppresses the proliferation of GBM cells in vitro and tumor growth in vivo, with reduced expression of proliferation marker MKI67 .

• Subtype association: PAK1 expression is particularly high in the mesenchymal (MES) subtype of GBM, which is associated with shorter survival and poor radiation response .

This data suggests PAK1 as a potential therapeutic target in GBM, particularly through disrupting its autophagy-promoting functions under hypoxic tumor conditions.

How does PAK1 interact with autophagy machinery and what are the implications for disease?

PAK1 serves as a critical regulator of autophagy through multiple mechanisms:

• Direct phosphorylation of ATG5:

  • PAK1 directly phosphorylates ATG5 at threonine 101 (T101)

  • This phosphorylation enhances ATG12-ATG5-ATG16L1 complex formation

  • The complex is essential for autophagosome formation during early stages of autophagy

• Response to cellular stress:

  • Hypoxic conditions induce acetylation of PAK1 at lysine 420 (K420)

  • This post-translational modification enhances PAK1's interaction with ATG5

  • PAK1 knockdown reduces LC3B-II levels and autophagic puncta in hypoxia-treated GBM cells

• Transcriptional regulation:

  • PAK1 expression positively correlates with autophagy-related gene ontology terms

  • It shows positive association with 113 autophagy genes, including SQSTM1 and ATG3

  • This suggests PAK1 may also regulate autophagy at the transcriptional level

• Disease implications:

  • In GBM, PAK1-mediated autophagy promotes tumor cell survival under hypoxic conditions

  • PAK1 inhibition could potentially target cancer cells by disrupting this survival mechanism

  • The PAK1-autophagy axis represents a potential therapeutic target for cancers characterized by hypoxic microenvironments

These findings highlight the importance of PAK1 in coordinating autophagy responses to cellular stress and suggest new avenues for therapeutic intervention in cancers dependent on autophagy for survival.

Why might I observe different results with PAK1 (Ab-199) antibody compared to phospho-specific PAK1 antibodies?

Discrepancies between PAK1 (Ab-199) and phospho-specific antibodies can arise from several factors:

• Epitope specificity differences:

  • PAK1 (Ab-199) antibody recognizes total PAK1 around the Ser199 site, regardless of phosphorylation status

  • Phospho-specific antibodies (like anti-PAK1 phospho-S199) only detect PAK1 when phosphorylated at Ser199

  • This fundamental difference means they measure different biological parameters

• Sample preparation issues:

  • Phosphorylation states can be lost during sample processing if phosphatase inhibitors are not included

  • Different lysis buffers may preserve phospho-epitopes differently

  • Flash-freezing samples may better preserve phosphorylation compared to slow processing

• Biological variation:

  • Phosphorylation is dynamic and stimulus-dependent, while total protein levels change more slowly

  • Time course differences: phosphorylation may be transient while total protein remains constant

  • Spatial differences: phosphorylated PAK1 may localize to specific cellular compartments

• Experimental design considerations:

  • For comprehensive analysis, use both antibody types: total PAK1 (Ab-199) and phospho-specific antibodies

  • Calculate phosphorylation/total protein ratios for more meaningful comparisons

  • Include appropriate positive controls (e.g., cells treated with PAK1 activators like CDC42/RAC1)

When discrepancies occur, validate with additional techniques such as phosphatase treatment controls or mass spectrometry to confirm phosphorylation status.

How do I differentiate between PAK1 and PAK2 when using antibodies targeting conserved regions?

Differentiating between PAK1 and PAK2 requires careful experimental design due to their high sequence homology, particularly around the Ser199 region:

Comparative characteristics of PAK1 and PAK2:

Differentiation strategies:

• Molecular weight discrimination:

  • PAK1 runs at approximately 68 kDa on SDS-PAGE

  • PAK2 runs at approximately 62 kDa

  • Use gradient gels with extended run times for optimal separation

• Isoform-specific antibodies:

  • Use antibodies targeting unique regions of PAK1 (some commercial antibodies like Cell Signaling #2602 are validated not to cross-react with PAK2)

  • Compare with the PAK1 (Ab-199) antibody which may detect both isoforms due to conserved sequences

• Genetic manipulation:

  • Employ siRNA/shRNA knockdown specific to PAK1 or PAK2

  • Use PAK1/PAK2 knockout cell lines as definitive controls

  • Observe band disappearance corresponding to the specific isoform

• Mass spectrometry validation:

  • For definitive identification, use immunoprecipitation followed by mass spectrometry

  • This can identify unique peptides specific to each isoform

• Expression system controls:

  • Use recombinant PAK1 and PAK2 as positive controls

  • Include samples with known differential expression of PAK1 vs PAK2

When studying phosphorylation, remember that homologous phosphorylation sites exist in both proteins, requiring careful interpretation of results from antibodies recognizing conserved phosphorylation motifs.

What are the most common technical challenges when using PAK1 (Ab-199) antibody and how can they be addressed?

Researchers commonly encounter several technical challenges when working with PAK1 (Ab-199) antibody:

• Background or non-specific staining:

  • Solution: Optimize blocking conditions (try 5% BSA instead of milk); increase washing steps; test different antibody dilutions; use highly specific secondary antibodies; consider antigen retrieval optimization for IHC

  • Validation approach: Include antigen competition controls by pre-incubating antibody with immunogenic peptide

• Weak or absent signal:

  • Solution: Confirm PAK1 expression in your samples; enrich protein by immunoprecipitation; optimize protein extraction protocol; reduce antibody dilution; enhance detection systems; extend exposure times

  • Validation approach: Include positive control lysates from cell lines with known PAK1 expression (K562, 293, or 3T3 cells)

• Multiple bands in Western blots:

  • Solution: Verify if bands represent isoforms, degradation products, or post-translational modifications; optimize gel percentage and running conditions; ensure complete denaturation; add protease inhibitors during lysis

  • Validation approach: Compare band patterns with isoform-specific antibodies; perform knockdown experiments to confirm specificity

• Irreproducible results:

  • Solution: Standardize protocols; prepare fresh reagents; maintain consistent antibody lots; verify protein quantification; document experimental conditions comprehensively

  • Validation approach: Implement positive and negative controls for each experiment; consider multi-site replications

• Loss of phosphorylation during sample processing:

  • Solution: Add phosphatase inhibitors to all buffers; maintain samples at 4°C; process samples quickly; avoid repeated freeze-thaw cycles

  • Validation approach: Include phosphorylation-inducing positive controls; compare with phospho-specific antibodies

• Cross-reactivity with other proteins:

  • Solution: Increase antibody dilution; perform more stringent washing; block with normal serum from secondary antibody species

  • Validation approach: Confirm results with alternative PAK1 antibodies; validate with genetic manipulation approaches

Implementing these strategies will improve the reliability and interpretability of experiments using PAK1 (Ab-199) antibody across different applications.

How can PAK1 (Ab-199) antibody be used in studies of hypoxia-induced changes in tumor microenvironments?

PAK1 (Ab-199) antibody offers valuable research applications for investigating hypoxia-induced changes in tumor microenvironments:

• Monitoring total PAK1 expression changes:

  • Use PAK1 (Ab-199) antibody in combination with phospho-specific antibodies to track both expression and activation changes under hypoxia

  • Compare normoxic vs. hypoxic conditions in various cancer cell lines to establish PAK1 regulation patterns

  • Assess temporal dynamics of PAK1 expression during acute vs. chronic hypoxia exposure

• Spatial distribution analysis:

  • Employ immunohistochemistry with PAK1 (Ab-199) antibody to analyze PAK1 distribution in tumor sections

  • Map PAK1 expression relative to hypoxic regions (identified with HIF-1α or pimonidazole staining)

  • Correlate PAK1 levels with distance from tumor vasculature

• Post-translational modification studies:

  • Investigate how hypoxia affects PAK1 acetylation at K420 using acetyl-specific antibodies

  • Combine with PAK1 (Ab-199) antibody to calculate ratios of modified vs. total PAK1

  • Perform immunoprecipitation with PAK1 (Ab-199) followed by acetylation detection

• Protein-protein interaction networks:

  • Use PAK1 (Ab-199) for immunoprecipitation studies to capture PAK1 protein complexes

  • Compare PAK1 interactome under normoxic vs. hypoxic conditions

  • Validate specific interactions (e.g., with ATG5) using reciprocal co-immunoprecipitation

• Functional pathway analysis:

  • Combine PAK1 (Ab-199) antibody with antibodies against autophagy markers (LC3B, p62/SQSTM1)

  • Assess correlation between PAK1 levels and autophagy activation in hypoxic regions

  • Perform co-localization studies using immunofluorescence

This research approach would provide comprehensive insights into how PAK1 mediates cellular adaptation to hypoxic stress in tumors, potentially revealing new therapeutic opportunities.

What emerging techniques can enhance the utility of PAK1 (Ab-199) antibody in research?

Several cutting-edge methodologies can extend the research applications of PAK1 (Ab-199) antibody:

• Proximity ligation assay (PLA):

  • Combine PAK1 (Ab-199) with antibodies against potential interaction partners

  • Detect protein-protein interactions with single-molecule sensitivity

  • Visualize subcellular localization of PAK1-protein complexes in situ

  • Example application: Detect PAK1-ATG5 interactions under various cellular stresses

• CRISPR-mediated endogenous tagging:

  • Use CRISPR/Cas9 to introduce epitope tags into endogenous PAK1

  • Validate PAK1 (Ab-199) antibody specificity against tagged endogenous protein

  • Perform live-cell imaging of PAK1 dynamics with complementary approaches

• Mass cytometry (CyTOF):

  • Conjugate PAK1 (Ab-199) antibody with metal isotopes

  • Perform high-dimensional analysis of PAK1 expression across heterogeneous cell populations

  • Correlate PAK1 with dozens of other proteins simultaneously in tumor samples

• Spatial transcriptomics integration:

  • Combine PAK1 immunohistochemistry with spatial transcriptomics

  • Correlate PAK1 protein levels with gene expression patterns in the same tissue region

  • Map PAK1-associated transcriptional programs within the tumor microenvironment

• Single-cell western blotting:

  • Apply PAK1 (Ab-199) antibody in microfluidic single-cell western blot platforms

  • Analyze PAK1 expression heterogeneity at single-cell resolution

  • Correlate with cell cycle markers or differentiation states

• Super-resolution microscopy:

  • Utilize PAK1 (Ab-199) antibody with secondary antibodies compatible with STORM or STED

  • Achieve nanoscale resolution of PAK1 subcellular localization

  • Investigate PAK1 association with cytoskeletal structures or autophagosomes

These advanced techniques would provide unprecedented insights into PAK1 biology at molecular, cellular, and tissue levels, enhancing our understanding of its roles in normal physiology and disease.

How can researchers investigate the interplay between PAK1 phosphorylation at Ser199 and other post-translational modifications?

Investigating the crosstalk between PAK1 Ser199 phosphorylation and other post-translational modifications (PTMs) requires sophisticated experimental approaches:

• Sequential immunoprecipitation strategy:

  • First immunoprecipitation: Use antibodies against specific PTMs (acetylation, ubiquitination)

  • Second immunoprecipitation: Re-immunoprecipitate with PAK1 (Ab-199) antibody

  • Analysis: Determine what fraction of modified PAK1 is also phosphorylated at Ser199

  • Example application: Investigate whether K420 acetylation precedes or follows Ser199 phosphorylation

• Mass spectrometry-based PTM mapping:

  • Immunoprecipitate PAK1 using PAK1 (Ab-199) antibody

  • Perform high-resolution MS/MS analysis to identify all PTMs simultaneously

  • Quantify PTM stoichiometry across different cellular conditions

  • Create a comprehensive PAK1 PTM landscape under normal vs. stressed conditions

• Site-directed mutagenesis approach:

  • Generate PAK1 mutants: S199A (prevents phosphorylation) and S199D (phosphomimetic)

  • Assess how these mutations affect other PTMs (acetylation at K420, phosphorylation at T423)

  • Evaluate functional consequences through kinase assays and protein-protein interaction studies

  • Determine if Ser199 phosphorylation is a prerequisite for other modifications

• Pharmacological modification profiling:

  • Treat cells with specific kinase or deacetylase inhibitors

  • Monitor changes in PAK1 Ser199 phosphorylation relative to other modifications

  • Establish temporal sequence of modifications using time-course experiments

  • Example: Determine how anacardic acid (acetylation inhibitor) affects Ser199 phosphorylation

• In vitro reconstitution experiments:

  • Purify recombinant PAK1 with defined modifications

  • Assess how pre-existing modifications influence subsequent modification events

  • Determine how different modification combinations affect PAK1 catalytic activity and substrate specificity